Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-493 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MEDI-493 | DRUG | Active Comparator |
Inclusion Criteria: * The child must have been born at greater than or equal to 35 weeks gestation and be greater than or equal to 6 months of age at the time of randomization (child must be randomized on or before their 6-month birthday) * The child's parent or legal guardian must provide written ...
MEDI-493 is an investigational small molecule being studied for use in unhealthy children with a history of prematurity. It is currently in Phase 2 clinical development and is not approved by the FDA. The drug is being developed by AstraZeneca PLC.
MEDI-493 is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its pharmacokinetics, safety, and tolerability in a pediatric population with a history of prematurity.
MEDI-493 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical development for use in unhealthy children with a history of prematurity.
MEDI-493 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One clinical trial has been completed, and the drug is not currently in any active trials.
MEDI-493 has one completed clinical trial, NCT00240929, a Phase II randomized, double-blind, two-period cross-over study. The trial evaluated the pharmacokinetics, safety, and tolerability of a liquid formulation of the drug in 150 unhealthy children with a history of prematurity in the United States.
MEDI-493 is also known as palivizumab and is referred to as Synagis in the clinical trial title. The trial NCT00240929 evaluates a liquid formulation of palivizumab (MEDI-493, Synagis), indicating that MEDI-493 and Synagis are the same drug.